Pre-Made Pabinafusp Alfa Biosimilar, Fusion Protein targeting TFRC fused with iduronate-2-sulfatase: Recombinant therapeutic protein targeting CD71/IMD46/T9/TFR/TFR1/TR/TRFR/p90 for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Pabinafusp Alfa Biosimilar, Fusion Protein targeting TFRC fused with iduronate-2-sulfatase: Recombinant therapeutic protein targeting CD71/IMD46/T9/TFR/TFR1/TR/TRFR/p90 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Enzyme replacement therapy (ERT) improves somatic manifestations in mucopolysaccharidoses (MPS). However, because intravenously administered enzymes cannot cross the blood¨Cbrain barrier (BBB), ERT is ineffective against the progressive neurodegeneration and resultant severe central nervous system (CNS) symptoms observed in patients with neuronopathic MPS. Pabinafusp alfa is a human iduronate-2-sulfatase fused with a BBB-crossing anti-transferrin receptor (Tfr) antibody, which successfully deliver across the BBB into the CNS by way of TfR-mediated transcytosis and decrease heparan sulfate (HS) accumulations in the brain. pabinafusp alfa is effective against both the somatic and CNS symptoms of patients with MPS-II.
| Products Name (INN Index) | Pre-Made Pabinafusp Alfa Biosimilar, Fusion Protein targeting TFRC fused with iduronate-2-sulfatase: Recombinant therapeutic protein targeting CD71/IMD46/T9/TFR/TFR1/TR/TRFR/p90 |
|---|---|
| INN Name | pabinafusp alfa |
| Target | TFRC |
| Format | Fusion Protein |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – kappa |
| VD LC | IgG1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | JCR Pharmaceuticals Co.,?Ltd (Ashiya Japan) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TFRC |
| Package |
